Role of Chronic Inflammation in Myopia Progression: Clinical Evidence and Experimental Validation  by Lin, Hui-Ju et al.
EBioMedicine 10 (2016) 269–281
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperRole of Chronic Inﬂammation in Myopia Progression: Clinical Evidence
and Experimental ValidationHui-Ju Lin a,b, Chang-Ching Wei c,d, Ching-Yao Chang e,f, Ter-Hsin Chen g, Yu-An Hsu h, Yi-Ching Hsieh a,b,
Hsuan-Ju Chen i, Lei Wan b,e,j,⁎
a Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan
b School of Chinese Medicine, China Medical University, Taichung, Taiwan
c Department of Pediatrics, China Medical University Hospital, Taichung, Taiwan
d College of Medicine, China Medical University, Taichung, Taiwan
e Department of Biotechnology, Asia University, Taichung, Taiwan
f Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
g Graduate Institute of Veterinary Pathobiology, National Chung Hsing University, Taichung, Taiwan
h Institute of Molecular Medicine, National TsingHua University, Hsinchu, Taiwan
i Management Ofﬁce for Health Data, China Medical University Hospital, Taichung, Taiwan
j Department of Gynecology, China Medical University Hospital, Taichung, TaiwanAbbreviations: Systemic lupus erythematosus, SLE; t
monocular form deprivation, MFD; nuclear factor κB,
necrosis factor α, TNF-α; cyclosporine A, CSA; lipopolys
PGN; collagen I, COL1; muscarinic acetylcholine receptor
factor β, TGF-β; matrix metalloproteinase 2, MMP2; j
refractive error, RE; National Health Insurance Research
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁ
buffered saline, PBS; Dulbecco’s Modiﬁed Eagle Medium
FBS; Tris-buffered saline, TBS; 4',6-diamidino-2-phenylin
regulated kinase, ERK; protein kinase B, AKT; phosphoin
ratio, HR; conﬁdence interval, CI; retinal pigment epitheli
⁎ Corresponding author at: School of Chinese Medicine
91, Hsueh-Shih Road, Taichung 40402, Taiwan.
E-mail addresses: leiwan@mail.cmu.edu.tw, lei.joseph
http://dx.doi.org/10.1016/j.ebiom.2016.07.021
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 4 May 2016
Received in revised form 16 July 2016
Accepted 17 July 2016
Available online 19 July 2016Prevention and treatment of myopia is an important public problem worldwide. We found a higher inci-
dence of myopia among patients with inﬂammatory diseases such as type 1 diabetes mellitus (7.9%), uveitis
(3.7%), or systemic lupus erythematosus (3.5%) compared to those without inﬂammatory diseases
(p b 0.001) using data from children (b18 years old) in the National Health Insurance Research database.
We then examined the inhibition of myopia by atropine in Syrian hamsters with monocular form depriva-
tion (MFD), an experimental myopia model. We found atropine downregulated inﬂammation in MFD eyes.
The expression levels of c-Fos, nuclear factor κB (NFκB), interleukin (IL)-6, and tumor necrosis factor (TNF)-
αwere upregulated in myopic eyes and downregulated upon treatment with atropine. The relationship be-
tween the inﬂammatory response and myopia was investigated by treating MFD hamsters with the immu-
nosuppressive agent cyclosporine A (CSA) or the inﬂammatory stimulators lipopolysaccharide (LPS) or
peptidoglycan (PGN). Myopia progression was slowed by CSA application but was enhanced by LPS and
PGN administration. The levels of c-Fos, NF-κB, IL-6, and TNF-α were upregulated in LPS- and PGN-treated
eyes and downregulated by CSA treatment. These ﬁndings provide clinical and experimental evidence that
inﬂammation plays a crucial role in the development of myopia.ype 1 diabetes
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en access article under1. Introduction
The prevalence of myopia has rapidly increased in recent decades,
resulting in a signiﬁcant global public health concern (Morgan et al.,
2012; Pan et al., 2012). Globally, there are approximately 153 million
people over the age of 5 years who suffer from visual defects (8 million
of whom suffer from blindness) caused by uncorrected myopia and
other refractive errors (Resnikoff et al., 2008). Myopia is an important
and often undertreated eye disease. Although most cases of myopia
can be corrected with glasses, contact lenses, or refractive surgery, un-
corrected refractive errors still account for ~33% of visual impairments
(Dandona and Dandona, 2001; McCarty, 2006). High-degree myopia isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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macular and retinal complications. Myopia results primarily from ab-
normal elongation of the vitreous chamber of the eye (Curtin, 1985).
This condition is recapitulated in the monocular form deprivation
(MFD) animal model, which has been used to study myopia pathogen-
esis (McKanna and Casagrande, 1981). Eye elongation is associated
with remodeling of the sclera (Marzani and Wallman, 1997;
McKanna and Casagrande, 1981), loss of scleral tissue via reduced
connective tissue synthesis, and increased collagen I (COL1) degra-
dation, resulting in changes in the composition and ductility of the
sclera (McBrien et al., 2000; Rada et al., 2002). Recent studies in
monkeys showed that the retina—speciﬁcally, photoreceptors and
retinal pigment epithelium—plays an important role in modulating
eye growth and axial length (Smith et al., 2009; Smith et al., 2005;
Smith et al., 2007) by producing activating signals that promote
scleral tissue remodeling (Chen et al., 2012).
Animal studies ofmyopia have shown that atropine—a non-selective
muscarinic acetylcholine receptor (mAChR) antagonist—effectively
prevents the axial elongation, leading to myopia (Fan et al., 2007;
Rada et al., 2000; Shih et al., 1999). Atropine inhibits myopia pro-
gression in the tree shrew, monkey, chicken, guinea pig, rat, mice,
and Syrian hamster, and its effectiveness has also been demonstrat-
ed in human clinical trials (Shih et al., 1999; Shih et al., 2001). How-
ever, the mechanistic basis for this effect is still unclear (McBrien et
al., 2013).
Various molecules have been implicated in myopia progression.
In myopic eyes, transforming growth factor (TGF)-β and matrix
metalloproteinase (MMP)2 expression is elevated, whereas COL1
expression is downregulated (Lin et al., 2006). TGF-β regulates cel-
lular functions such as cell growth, differentiation, inﬂammation,
and wound healing, while MMP family members play major roles
in the breakdown of the extracellular matrix, tissue reconstruction
(Wojciechowski et al., 2010; Wojciechowski et al., 2013), and tis-
sue vascularization during the inﬂammatory response. The dysreg-
ulation of MMPs has also been proposed as a mechanism of
pathogenesis in myopic eyes (Guggenheim and McBrien, 1996;
Yang et al., 2010); MMP2 expression is upregulated in the sclera
of chicks and tree shrews in which myopia has been induced by
form deprivation (Guggenheim and McBrien, 1996; Jones et al.,
1996; Rada and Brenza, 1995; Rada et al., 1999). TGF-β regulates
the level of MMP2 via activation of nuclear factor (NF)-κB, a tran-
scription factor that modulates the expression of various inﬂamma-
tory cytokines in ﬁbroblasts (Wang et al., 2011b).
Several reports have proposed a role for inﬂammation in myo-
pia progression. A 26-year follow-up of patients with juvenile
chronic arthritis (JCA) revealed myopic refractive errors (REs) in
a greater fraction of these patients than in age-matched control
subjects, suggesting a correlation between JCA and myopia. The
study also suggested that the higher incidence of myopia was due
to the weakening of scleral connective tissue as a result of chronic
inﬂammation (Fledelius et al., 2001; Herbort et al., 2011). In addi-
tion, acute onset myopia may be a presenting feature of systemic
lupus erythematosus (SLE) (Ayazi et al., 1982; Kamath et al.,
2013; Shu et al., 1992). In this study, we provide clinical and exper-
imental evidence to support an association between inﬂammation
and myopia progression.
2. Materials and Methods
2.1. Nationwide Population-based Retrospective Cohort Study
2.1.1. Data Source
The National Health Insurance Research database (NHIRD),
maintained by the National Health Research Institutes, is popula-
tion-based and derived from the claims data of the National Health
Insurance program, a mandatory-enrollment, single-paymentsystem created in 1995, covering over 99% of Taiwan's population
until the end of 2014. This ﬁle contained all medical claims and
the information of insurants and provided a valuable resource,
unique opportunity, and sufﬁciently large sample size to pursue
the objectives addressed by this study. The high validity of the diag-
nostic data from the NHIRD has been previously reported (Cheng
et al., 2011; Kang et al., 2010). Files for children (age b18 years) in-
cluded 50% of those randomly selected from the Children's Regis-
tries from 1996 to 2008. The index of inﬂammatory diseases,
including SLE, type 1 diabetes mellitus (T1DM), and uveitis, was
coded based on the International Classiﬁcation of Diseases, 9th Re-
vision, Clinical Modiﬁcation (ICD-9-CM). Urbanization level was di-
vided into seven categories based on a previous report (Liu et al.,
2006), with levels 1 and 7 deﬁned as highest and lowest, respec-
tively. Because there were few children in levels 5–7, these were
combined with level 4. Because of the personal electronic data pri-
vacy regulation, insurants' identities were encrypted before data
were sent to the researcher; nonetheless, the study was approved
the Institutional Review Board in China Medical University Hospital
(CRREC-103-048).
2.1.2. Study Sample
Children newly diagnosed with SLE between 2000 and 2004 were
identiﬁed from a database based on the ICD-9CM code (ICD-9-CM
code 373.34, 695.4, and 710.0) as SLE cohort, and the date of SLE di-
agnosis was considered as the index date. We excluded patients with
myopia (ICD-9-CM code 367.1), cataract (ICD-9-CM code: 366 and
743.3), glaucoma (ICD-9-CM code: 365), and uveitis (ICD-9-CM
code: 360.11, 360.12, 362.18, 363.00, 363.01, 363.03, 363.05–
363.08, 363.1×, 363.20, 363.21, 363.4×, 364.00–364.02, 364.04,
and 364.1×–364.3×) before the index date. For each patients with
SLE, four insured children were randomly selected from children
without SLE, frequency-matched on sex, age (per 1 years), and
index year using the same inclusion criteria as that of the SLE cohort,
as control cohort. The index date for non-SLE group was randomly
assigned a day and month and the index year was assigned the
same year as the SLE group. We retrieved 1188 patients with SLE
and 4752 children without SLE. The SLE and non-SLE cohorts were
followed from index date to myopia diagnosis, withdrawal from
the NHI program, or the end of 2008, whichever occurred ﬁrst. Sim-
ilar analyses to investigate the occurrence of myopia were also per-
formed in T1DM (ICD-9-CM code: 250.X1 and 250.X3) with an
appropriate non-T1DM cohort. The T1DM were determined through
record linkage with the catastrophic illness registry of NHIRD. For
uveitis (ICD-9-CM code: 360.11, 360.12, 362.18, 363.00, 363.01,
363.03, 363.05–363.08, 363.1×, 363.20, 363.21, 363.4×, 364.00–
364.02, 364.04, and 364.1×–364.3×) cohort, we include the uveitis
cohort from 2000 to 2005 and we exclude those patients with myo-
pia before the index date. The non-uveitis cohort for uveitis was fre-
quency-matched in sex, age (per 1 years), parents' occupational
status, urbanization and index year.
2.2. Animals
Golden Syrian hamsters aged 3 weeks and weighing 80–90 g
were used for the experiments. In total, 160 hamsters were used
in this study. Albino and pigmented guinea pigs aged three weeks
were also used in this study. The animals were kept under a 12-
hour light/12-hour dark cycle. All procedures were approved by
the Institutional Animal Care and Use Committee of China Medical
University and were in accordance with the guidelines for the Use
of Animals in Ophthalmic and Vision Research. Hamsters were
raised with right eyelid fusion for 21 days. MFD was induced in
the right eye (with the left eye serving as a control) of animals ran-
domly assigned to treatment or control groups (n = 10 animals
each) receiving daily applications of drug or phosphate-buffered
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pigs by covering the right eye with a cloth attached to the skin at a
distance of at least 1 cm from the eye for 21 days. Guinea pigs
were randomly assigned to treatment or control groups (n= 10 an-
imals each) receiving daily applications of drug or PBS, respectively,
to both eyes.
2.3. Cell Culture
ARPE-19 human retinal pigment epithelial cells were obtained
from Bioresource Collection and Research Center, HsinChu, Taiwan
(BCRC; BCRC-60,383). Cells were cultured in Dulbecco's Modiﬁed
Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) at 37 °C
and 5% CO2, with medium replacement every 3–4 days. Sclera were
placed in a 60-mm culture dish in DMEM supplemented with 10%
FBS to isolate primary scleral ﬁbroblasts; those from fewer than
three passages were used in experiments. Cells were seeded in 6-
well plates (1 × 105 cells/well) and treated with lipopolysaccharide
(LPS) at 100 ng/ml or left untreated for 4 h, followed by 100 μM at-
ropine for 24 h. Cell lysates were collected for quantitative (q)PCR
to determine gene expression levels.
2.4. cDNA Microarray Analysis
Sclera tissues were obtained from eyes with or without MFD.
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA in-
tegrity and purity were determined using an Agilent Bioanalyzer.
Five different total RNA samples were pooled together (equal
amounts) for cDNA microarray analysis. cDNA microarray analysis
was performed using Affymetrix GeneChip Human Genome U133
Plus 2.0 and the procedures followed the manufacturer's guidance.
cDNA microarrays were scanned using a GeneArray Scanner. The
image ﬁles (.cel format) were analyzed by DNA Chip Analyzer soft-
ware. Genes that were differentially expressed with a difference
N1.2 fold between control eyes and myopic eyes were selected for
ingenuity pathway analysis.
2.5. Physiological Measurements and Tissue Preparation
RE, i.e., the spherical component RE, which is deﬁned as the mean
RE in horizontal and vertical meridians, was measured using a hand-
held streak retinoscope. Animals were anesthetized with 10% ether
in O2. Ocular refraction was evaluated at the start and end of the ex-
periment. At the end of the study, animals were sacriﬁced by CO2 as-
phyxiation according to the guidelines of the Public Health Service,
Ofﬁce of Laboratory Animal Welfare, National Institutes of Health,
and American Association of Veterinary Medicine. Eyes were enucle-
ated using a razor blade on an ice plate under a surgical microscope
(Topcon, Tokyo, Japan) by making a cut perpendicular to the anteri-
or-posterior axis approximately 1 mm posterior to the ora serrata.
The iris and ciliary body of the anterior segment of the eye were
separated. Posterior sclera were excised using a 7-mm diameter tre-
phine. The axial lengths were determined by A-scan ultrasonography
(PacScan 300 Plus, New York, USA). The average of 10 different mea-
surements was used.
2.6. Gene Expression Proﬁling by PCR Array
Total RNA of sclera tissues was isolated using an RNeasy Mini
kit (Qiagen) and used for PCR array analysis. RNA integrity and
purity were determined using an Agilent Bioanalyzer. Total RNA
(1 μg) in a 20-μl ﬁnal volume was reverse-transcribed using the
High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Expression of genes involved in myopia progression
was determined by using 96-well RT2 Proﬁler PCR Arrays-HumanAutophagy (Qiagen, Frederick, MD, USA) in a LightCycler 480 PCR
system (Roche, Germany).
2.7. Immunoﬂuorescence Staining
Primary sclera ﬁbroblast cells plated on cover slides were washed
with Tris-buffered saline (TBS) and subsequently ﬁxed with 4% para-
formaldehyde and washed twice with TBS before blocking with 1%
bovine serum albumin, 0.1% Triton X-100 for 1 h. Cells were incubat-
ed with anti-MMP2 or anti-collagen I antibodies for 1 h. Cells were
washed three times with TBS and incubated with the appropriate
secondary antibody and DAPI (4′,6-diamidino-2-phenylindole)
DNA stain. After three washes with TBS, cells were imaged using
ﬂuorescence microscopy. All experiments were performed at least
in triplicate.
2.8. Analysis of MMP2 and MMP9 Activity
Here, 1 × 106 cells were seeded in 24-well plates for at least 12 h.
Cells were washed with PBS three times and incubated with culture
medium without FBS in the presence or absence of 1 μg/ml LPS or
1 μg/ml LPS + 100 μM atropine or 1 μg/ml LPS + 50 μM diacerein.
Culture supernatants were collected after 48 h and mixed with an
equal volume of loading buffer (125 mM Tris–HCl, pH 6.8, 3% SDS,
40% glycerol, 0.02% bromophenol blue). To measure MMP-2/MMP-
9 activity, samples were separated by 8% SDS-PAGE containing 0.1%
gelatin.
2.9. Western Blot Analysis
ARPE-19 cells were treated with PBS (control), 100 ng/ml lipo-
polysaccharide (LPS; Sigma), or LPS + 100 μM atropine for 30 min.
After treatment, 30 μg of the total cell lysate was subjected to sodi-
um dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
followed by immunoblot analysis. The primary antibodies used
included extracellular signal-regulated kinase (ERK) (Thr202/
Tyr204), protein kinase B (AKT) (Ser473), phosphoinositide 3-ki-
nase (PI3K) (p85(Tyr458)/p55(Tyr199)), NF-κB (p65, Ser536), and
c-Fos (Ser32) (Cell Signaling, Beverly, MA). Anti-rabbit and anti-
mouse secondary antibodies conjugated with horseradish peroxi-
dase were also used. Immunoreactive protein bands were detected
using an enhanced chemiluminescence kit (ECL, Pierce, Thermo
Fisher Scientiﬁc, Pittsburgh, PA, USA). Equal loading was conﬁrmed
by probing the blots with an anti-β-actin antibody (Abcam, Cam-
bridge, MA, USA) as well as antibodies against anti-ERK, AKT, PI3K,
NF-κB, and c-Fos.
2.10. qPCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA), and 5 μg RNA was reverse-transcribed to cDNA
using the Superscript First Strand Synthesis system (Invitrogen,
Carlsbad, CA). Primers and probes used for qPCR were selected from
theUniversal Probes Library (Roche,West Sussex, UK). Transcript levels
were normalized to that of glyceraldehyde 3-phosphate dehydrogenase
in each sample.
2.11. Immunohistochemistry
Eyes were collected from atropine-treated and control animals,
embedded in parafﬁn, and cut at a thickness of 20 μm; sections
were collected on glass slides. Antigen retrieval was performed by
boiling the slides in citrate buffer (pH 6.0); sections were then
stained with antibodies against interleukin (IL)-6, tumor necrosis
factor (TNF)-α, TGF-β, MMP2, c-Fos, NF-κB, and mAChR 1 and 3.
Table 1
Demographic factors and comorbidity of study participants according to type I diabetes mellitus, uveitis, and systemic lupus erythromatosus.
T1DM control
(n= 2196)
T1DM (n=
549)
p-Value Uveitis control
(n= 3120)
Uveitis (n=
780)
p-Value SLE control (n
= 4752)
SLE (n= 1188) p-Value
Variable n % n % n % n % n % n %
Gender 0.99 0.99 0.99
Girl 1180 53.73 295 53.73 1272 40.77 318 40.77 3736 78.62 934 78.62
Boy 1016 46.27 254 46.27 1848 59.23 462 59.23 1016 21.38 254 21.38
Age, years 0.99 0.99 0.99
1–6 636 28.96 159 28.96 692 22.18 173 22.18 560 11.78 140 11.78
7–12 904 41.17 226 41.17 944 30.26 236 30.26 1480 31.14 370 31.14
13–18 656 29.87 164 29.87 1484 47.56 371 47.56 2712 57.07 678 57.07
Means (SD) 9.93 (4.62) 9.91 (4.61) 0.93 11.56 (4.74) 11.59 (4.74) 0.99 12.77 (4.07) 12.79 (4.07) 0.91
Urbanization 0.46 0.99 0.74
Level 1 (highest) 614 27.96 141 25.68 927 29.62 231 29.62 1331 28.01 333 28.03
Level 2 703 32.01 170 30.97 1020 32.69 255 32.69 1486 31.27 378 31.82
Level 3 405 18.44 115 20.95 632 20.26 158 20.26 903 19 210 17.68
Level 4 (lowest) 474 21.58 123 22.4 544 17.44 136 17.44 1032 21.72 267 22.47
Parents' occupational status 0.05 0.99 0.46
White collar 1250 56.92 289 52.64 1780 57.05 445 57.05 2629 55.32 665 55.98
Blue collar 709 32.29 182 33.15 992 31.79 248 31.79 1659 34.91 421 35.44
Other 237 10.79 78 14.21 348 11.15 87 11.15 464 9.76 102 8.59
Abbreviations: T1DM, type 1 diabetes mellitus; SLE, systemic lupus erythromatosus; SD, standard deviation.
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2.12. Statistical Analysis
Patients and control groups were compared in terms of the distri-
bution of demographic factors, including sex, age, urbanization, and
parent's occupation with the χ2 test. The incidence rates of myopia
were calculated by using the number of developed myopia dividingTable 2
Cox model measured hazard ratio and 95% conﬁdence intervals of myopia associated with inﬂ
Variables Crude Adjusted▲ Crude
HR (95% CI) HR (95% CI) HR (95% CI)
Disease T1DM Uveitis
No 1 1 1
Yes 1.55 (1.27–1.90)⁎⁎⁎ 1.57 (1.29–1.92)⁎⁎⁎ 1.46 (1.16–1.8
Gender
Girl 1 1 1.20 (0.98–1.4
Boy 0.81 (0.67–0.96)⁎ 0.79 (0.66–0.95)⁎ 1
Age, years
1–6 4.87 (3.24–7.33)⁎⁎⁎ 4.86 (3.23–7.31)⁎⁎⁎ 7.49 (4.94–11.
7–12 3.79 (2.53–5.70)⁎⁎⁎ 3.78 (2.52–5.69)⁎⁎⁎ 4.68 (3.07–7.1
13–18 1 1 1
Urbanization
Level 1 (highest) 1 1 1
Level 2 0.88 (0.70–1.10) 0.89 (0.71–1.12) 0.88 (0.68–1.1
Level 3 0.94 (0.73–1.21) 0.92 (0.71–1.19) 0.78 (0.58–1.0
Level 4 (lowest) 0.80 (0.62–1.04) 0.86 (0.66–1.12) 0.79 (0.57–1.1
Parents' occupational status
White collar 1 1 1
Blue collar 0.7 (0.57–0.86)⁎⁎⁎ 0.75 (0.61–0.93)⁎⁎ 0.75 (0.59–0.9
Other 0.72 (0.53–0.98)⁎ 0.71 (0.52–0.96)⁎ 0.70 (0.49–1.0
Abbreviation: T1DM, type 1 diabetes mellitus; SLE, systemic lupus erythematosus; HR, hazard
▲: Multivariable analysis including T1DM, gender, age (categorical), urbanization, and parents
▼: Multivariable analysis including uveitis, gender, age (categorical), urbanization, and parent
△: Multivariable analysis including SLE, gender, age (categorical), urbanization, and parent’ oc
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.by person-years at risk in both cohorts. We estimated the cumulative
incidence of myopia using the Kaplan–Meier method, and the signif-
icance of these curves were assessed by the log-rank test. The Cox
proportional hazards model was used to calculate the hazard ratio
(HR) and 95% conﬁdence interval (CI) of myopia in patients with in-
ﬂammatory diseases in comparison to those of controls. All analyses
were performed with SAS statistical software (version 9.4 for Win-
dows; SAS Institute, Inc., Cary, NC, USA). Statistical signiﬁcance was
determined as p b 0.05.ammatory diseases and covariates.
Adjusted▼ Crude Adjusted△
HR (95% CI) HR (95% CI) HR (95% CI)
SLE
1 1 1
5)⁎⁎ 1.47 (1.16–1.86)⁎⁎ 1.44 (1.21–1.72)⁎⁎⁎ 1.47 (1.23–1.74)⁎⁎⁎
8) 1.14 (0.93–1.41) 1 1
1 1.08 (0.91–1.29) 0.88 (0.74–1.04)
35)⁎⁎⁎ 7.83 (5.15–11.89)⁎⁎⁎ 7.16 (5.55–9.24)⁎⁎⁎ 7.4 (5.72–9.56)⁎⁎⁎
3)⁎⁎⁎ 4.82 (3.16–7.34)⁎⁎⁎ 3.72 (2.91–4.76)⁎⁎⁎ 3.74 (2.92–4.78)⁎⁎⁎
1 1 1
1 1 1
3) 0.78 (0.60–1.01) 0.90 (0.74–1.09) 0.89 (0.73–1.08)
5) 0.68 (0.50–0.92)⁎ 0.95 (0.76–1.19) 0.94 (0.75–1.18)
0) 0.87 (0.63–1.22) 0.89 (0.72–1.10) 0.90 (0.72–1.13)
1 1 1
5)⁎ 0.78 (0.61–1.00) 0.82 (0.70–0.97)⁎ 0.88 (0.74–1.05)
0) 0.69 (0.48–0.99)⁎ 0.7 (0.52–0.93)⁎ 0.7 (0.52–0.94)⁎
ratio; CI, conﬁdence interval.
' occupational status.
’ occupational status.
cupational status.
Table 3
Incidence density rates and hazard ratios of myopia stratiﬁed by the severity of inﬂammatory diseases.
Diseases Average frequency for medical visit, per years N Event no. Person-years IR Adjusted HR (95% CI)★ p for trend
T1DM control 2196 366 10,083.49 36.3 1.00 b0.001
T1DM cohort b13 187 31 836.09 37.08 1.09 (0.75–1.57)
13–17 212 59 935.54 63.06 1.71 (1.30–2.25)⁎⁎⁎
N17 150 43 574.27 74.88 1.93 (1.41–2.65)⁎⁎⁎
Uveitis control 3120 267 11,873.05 22.49 1.00 b0.001
Uveitis cohort ≤1 263 19 1411.26 13.46 0.52 (0.32–0.82)⁎⁎
2–3 260 30 939.56 31.93 1.48 (1.01–2.16)⁎
≥4 257 45 507.37 88.69 5.76 (4.15–8.00)⁎⁎⁎
SLE control 4752 508 17,320.17 29.33 1.00 b0.001
SLE cohort ≤1 581 75 2573.09 29.15 0.90 (0.70–1.14)
2–3 137 24 336.57 101.02 3.62 (2.55–5.13)⁎⁎⁎
≥4 470 62 1124.71 55.13 2.59 (1.98–3.40)⁎⁎⁎
Abbreviation: T1DM, type 1 diabetes mellitus; SLE, systemic lupus erythematosus; IR, incidence density rates, per 1000 person-years; HR, hazard ratio; CI, conﬁdence interval.
★: Adjusted for gender, age (continuous), urbanization, and parents' occupational status in Cox proportional hazards regression.
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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3.1. Association Between Inﬂammatory Disorders and Subsequent Myopia
Risk
A retrospective cohort study was conducted using data from chil-
dren (b18 years old) in theNHIRD to determinewhether the inﬂamma-
tory diseases T1DM, uveitis, and SLE are associatedwith the incidence of
myopia. Al total of 549 T1DM, 780 uveitis, and 1188 SLE patients were
newly diagnosed and randomly matched with regard to age, sex, and
index yearwith subjects without T1DM, uveitis, or SLE from the general
population in a 1:4 ratio (Table 1). Cohorts were followed until the end
of 2008, when the incidence of myopia was assessed. The risks of myo-
pia was higher by 1.57 fold (95% CI = 1.27–1.92) in T1DM, 1.47 fold
(95% CI = 1.16–1.86) in uveitis, and 1.47 fold (95% CI = 1.23–1.74) in
SLE cohorts than in controls (Table 2). The data in Table 3 show that pa-
tients with T1DM who visited clinics N17 times per year exhibited a
1.93-fold increased risk ofmyopia afterwe adjusted for age, sex, and ur-
banization (95% CI, 1.41–2.65) compared with the control cohort. The
risk of myopia development increased from 1.09 (95% CI, 0.75–1.57)
in patients with b13 medical visits to 1.71 (95% CI, 1.30–2.25) in pa-
tients with 13–17 medical visits and further increased to 1.93 (95% CI,
1.41–2.65) in patients with ≥17 medical visits compared with the con-
trol cohort (trend test, p b 0.001). For uveitis patients, the risk ofmyopia
development increased from 0.52 (95% CI, 0.32–0.82) in patients with
b1medical visit to 1.48 (95% CI, 1.01–2.16) in patientswith 2–3medical
visits and further increased to 5.76 (95% CI, 4.15–8) in patients with ≥4
medical visits compared with the control cohort (trend test, p b 0.001).
For SLE patients, the risk of myopia development increased from 0.90
(95% CI, 0.70–1.14) in patients with b1 medical visit to 3.62 (95% CI,
2.55–5.13) in patients with 2–3medical visits; however, it was reduced
to 2.59 (95% CI, 1.98–3.40) in patients with ≥4 medical visits compared
with the control cohort (trend test, p b 0.001). The cumulative incidence
of myopia by the end of the follow-up period was 7.9%, 3.7%, and 3.5%
higher in the T1DM, uveitis, and SLE groups, respectively (Fig. 1a–c)
than in control subjects. These ﬁndings provide a clinical correlation
for the association between inﬂammatory diseases and the occurrence
of myopia.
3.2. Genes Involved in Inﬂammation are Upregulated in Myopia
To study the role of inﬂammation inmyopia progression, a PCR array
for inﬂammatory cytokines and receptors was used to determine the
differential expression of genes in a MFD animal model. After 21 days,
transcript levels for the transcription factors c-Fos and NF-κB were1.25 and 1.52 fold higher, respectively, in sclera of MFD eyes com-
pared to that of non-MFD eyes (p b 0.05) (Table 4). The same pattern
was observed for various inﬂammatory cytokines including IL-6
(2.05 fold), TNF-α (1.54 fold), TGF-β (1.49 fold), and IL-1β (1.87
fold) (p b 0.05). Conversely, the expression of the anti-inﬂammatory
cytokine IL-10 was 0.58 fold lower in MFD than in non-MFD eyes
(p b 0.05). Because atropine affects both the sclera and retina, the dif-
ferential expression of inﬂammatory genes was examined in human
retinal pigment epithelial cells (ARPE-19) and scleral ﬁbroblasts. The
expression ofmAChR 1 and 3, c-Fos, IL-6, IL-1β, TGF-β, TNF-α, and NF-
κBwas upregulated by LPS treatment, but this effect was suppressed
in both cell types in the presence of atropine (p b 0.05). In contrast,
IL-10 expression was suppressed by LPS and enhanced by atropine
(p b 0.05). These results suggest that the inﬂammatory response is
linked to myopia progression.
To study the molecular mechanism of how atropine inhibited
inﬂammation, ARPE-19 cells were treated with LPS or LPS/atro-
pine for 4 h. The activation of ERK and its downstream signaling
molecule c-FOS by LPS was inhibited by atropine treatment. Atro-
pine treatment also inhibited the LPS activation of PI3K, AKT, and
NF-κB (Fig. 2a). Similar results were found in primary RPE cells
isolated from Syrian hamsters (Fig. 2a). These results indicate
that atropine inhibits inﬂammation through downregulation of
the ERK-c-FOS and PI3K-AKT-NF-κB pathways. Moreover, we
found that atropine decreased the expression levels of MMP2
and increased COL1 expression in primary sclera ﬁbroblasts iso-
lated from Syrian hamster (Fig. 2b). MMP2 activity was increased
in both RPE cells and sclera ﬁbroblasts activated by LPS, and de-
creased by atropine and diacerein (an anti-inﬂammatory com-
pound) (Fig. 2c, d).
After MFD, we found a time-dependent increase in the expression of
MMP2 and TGFβ and a time-dependent decrease of collagen I levels in
the retina and sclera from day 2 to day 21 by immunohistochemistry
(Fig. 3a). The same trend was also observed for the expression levels
of NF-κB, c-FOS, IL-6, and TNF-α (Fig. 3b).
3.3. Myopia Progression is Inhibited by Atropine
The change in RE for the PBS-treated MFD group was −7.22 ±
0.22 for MFD eyes. The change in RE decreased as a function of atro-
pine concentration: at 0.125%, 0.5%, and 0.1% atropine, the changes
in RE values were −5.45 ± 0.07, −4.89 ± 0.18, and −4.74 ±
0.39 D, respectively, for the MFD eye (ANOVA p b 0.001; Fig. 4a).
The changes in axial length in the control and 0.125%, 0.5%, and
0.1% atropine groups were 1.04 ± 0.12, 0.80 ± 0.09, 0.75 ± 0.26,
Fig. 1. Association between systemic inﬂammatory diseases and myopia incidence.
Cumulative incidence of myopia is shown for control subjects and patients with (a) type
I diabetes mellitus, (b) uveitis, or (c) systemic lupus erythromatosus.
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suggest that atropine administration inhibits myopia progression.
To conﬁrm the induction of myopia in our animal model, we de-
termined the expression levels of TGF-β and MMP2 in the sclera by
quantitative real-time PCR. Expression levels of TGF-β and MMP2
were higher by 1.49 and 1.59 fold, respectively, in MFD eyes
(p b 0.05) (Table 4). Although the expression of mAChR2, 4, and 5was similar between groups, mAChR1 and 3 levels were 1.54 and
1.68 fold higher, respectively, in MFD than in non-MFD eyes
(p b 0.05) (Table 4).
mAChR1 and 3 expression levels were higher in the sclera of the
MFD than in the non-MFD eye; mAChR1 and 3 were downregulated
in MFD eyes after atropine treatment as compared to the levels in
PBS-treated MFD eyes (Fig. 4c). Compared to PBS treatment, treat-
ment with 1% atropine decreased MMP2 expression and increased
COL1 expression in the sclera of MFD eyes, as determined by immu-
nohistochemistry (Fig. 4d). The TGF-β level was also upregulated in
both the retina and sclera by MFD, but this effect was suppressed
by atropine (Fig. 4e). These results indicate that the expression of
genes that promote myopia progression via tissue remodeling is al-
tered by MFD but corrected by atropine treatment. The expression
of c-Fos and NF-κB in the retinas of MFD eyes was higher than that
in non-MFD eyes, but was suppressed by treatment with 1% atropine
(Fig. 4f; Supplementary Figs. 1, 2). IL-6 and TNF-α immunoreactivity
in the retina was elevated in MFD eyes, but the expression of these
factors was reduced by application of 1% atropine. Conversely, IL-
10 expression was elevated following atropine treatment (Fig. 4g;
Supplementary Figs. 1, 2). These results indicate that atropine in-
hibits myopia progression through downregulation of inﬂammation
in the eye.3.4. Suppression of Inﬂammation Inhibits the Progression of Myopia
To determinewhether decreased inﬂammation inhibitsmyopia pro-
gression, the immunosuppressive agent cyclosporine A (CSA) was ap-
plied to the eyes of hamsters and the RE was measured on day 21. The
changes in RE for the PBS and CSA-treated groups were−3.77 ± 0.48
and−2.29 ± 0.50 D, respectively (p b 0.0001; Fig. 5a), indicating that
the progression of myopia was blocked. This ﬁnding was supported by
the observation of concomitant decreases in MMP2 and TGF-β expres-
sion (Fig. 5b).
To test whether increased inﬂammation enhances the progres-
sion of myopia, LPS and peptidoglycan (PGN) (500 ng/ml), which
are inducers of inﬂammation originating from Gram-negative and -
positive bacterial cell walls, respectively, were applied to the eyes
of MFD mice every second day for 21 days. The changes of RE for
PBS, LPS, and PGN-treated animals were −4.27 ± 0.49, −5.90 ±
0.54, and −4.90 ± 0.83 D for occluded eyes, respectively (Fig. 5c;
p b 0.0001). We also found an increase in RE in unblocked eyes. The
changes of RE for PBS, LPS and PGN-treated animals were −2.58 ±
0.36, −4.13 ± 0.9 and −5.03 ± 0.43 D for unblocked eyes, respec-
tively, suggesting a direct link between inﬂammation and myopia
progression (Fig. 5c; p b 0.01). The decline in RE was accompanied
by upregulation of MMP2 and TGF-β (Fig. 5d). To further evaluate
this mechanism, LPS and PGN were applied to the eyes of hamsters
without MFD. After 21 days, the changes of RE for the PBS-treated
group were −0.88 ± 0.18 and −0.18 ± 0.57 D for the right and
left eyes, respectively. These values declined to −3.69 ± 0.57 and
−3.95 ± 0.97 D, respectively, upon LPS treatment, and −3.03 ±
1.04 and −3.55 ± 0.35, respectively, in PGN-treated eyes, and
these differences were statistically signiﬁcant with respect to the
PBS-treated group (p b 0.001; Fig. 5e). These changes occurred con-
currently with the upregulation of TGF-β and MMP2 expression
(Fig. 5f).
CSA reduced c-Fos and NF-κB expression (Fig. 6a) that was stimulat-
ed by LPS or PGN (Supplementary Fig. 3). IL-6 and TNF-α levels, which
were increased by LPS or PGN treatment (Supplementary Fig. 4), were
decreased by CSA (Fig. 6b); IL-10 immunoreactivity was reduced by
LPS or PGN (Supplementary Fig. 4) but increased after CSA treatment
(Fig. 6b). Taken together, these results indicate that induction of inﬂam-
mation causes acceleration of myopia, which can be reversed by appli-
cation of anti-inﬂammatory agents.
Table 4
Gene expression levels in scleral tissue and ﬁbroblasts and retinal piement epithelial cells as determined by real-time PCR.
Gene symbola Accession No. Sclera tissue Retinal pigment epithelial cell Sclera ﬁbroblast
CLb CRb LPSc LPS-atropined LPSc LPS-atropined
Chrm 1 NM_080773.1 1 ± 0.17 1.54 ± 0.12# 1.54 ± 0.21 0.65 ± 0.16# 1.49 ± 0.18 0.73 ± 0.11#
Chrm 2 NM_031016.1 1 ± 0.14 0.98 ± 0.15# 0.55 ± 0.23 1.96 ± 0.15# 1.48 ± 0.17 1.24 ± 0.14
Chrm 3 NM_012527.1 1 ± 0.15 1.68 ± 0.21# 1.27 ± 0.18 0.75 ± 0.21# 1.58 ± 0.15 0.70 ± 0.23#
Chrm 4 NM_031547.1 1 ± 0.2 0.89 ± 0.3 0.84 ± 0.07 0.91 ± 0.25 1.07 ± 0.23 1.11 ± 0.17
Chrm5 NM_017362.4 1 ± 0.22 0.84 ± 0.14 0.74 ± 0.11 0.83 ± 0.15 0.93 ± 0.15 0.98 ± 0.12
Fos DQ089699.1 1 ± 0.1 1.25 ± 0.18# 2.39 ± 0.18 0.69 ± 0.17# 1.00 ± 0.11 0.93 ± 0.17
IL10 NM_012854.2 1 ± 0.13 0.58 ± 0.1# 0.46 ± 0.17 1.92 ± 0.16# 0.56 ± 0.19 1.05 ± 0.21#
IL-6 NM_012589.1 1 ± 0.18 2.05 ± 0.26# 3.28 ± 0.17 0.89 ± 0.26# 3.02 ± 0.16 0.79 ± 0.18#
IL1b NM_031512.2 1 ± 0.12 1.87 ± 0.14# 2.63 ± 0.15 0.57 ± 0.19# 2.84 ± 0.21 0.75 ± 0.13#
Tgfb1 NM_021578.2 1 ± 0.13 1.49 ± 0.12# 1.48 ± 0.14 0.76 ± 0.13# 2.15 ± 0.23 0.48 ± 0.24#
Tnfa AF269159.1 1 ± 0.15 1.54 ± 0.15# 4.3 ± 0.25 0.82 ± 0.11# 1.49 ± 0.15 0.80 ± 0.2#
NFkB AF079314.1 1 ± 0.1 1.52 ± 0.14# 1.99 ± 0.12 0.76 ± 0.17# 4.50 ± 0.27 0.36 ± 0.3#
MMP2 NM_031054.2 1 ± 0.19 1.59 ± 0.08# 1.73 ± 0.14 0.78 ± 0.24# 1.79 ± 0.17 0.74 ± 0.19#
# Statistically signiﬁcant (p b 0.05) by the Student's t-test for paired comparisons between LPS and LPS+atropine.
a Genes that were differentially expressed between CR and CL in the cDNA microarray.
b CR, form-deprived right eye (occluded eye); CL, left eye.
c Cells were treated with 100 ng/ml LPS for 4 h.
d Cells were treated with 100 ng/ml LPS and 100 μM atropine for 4 h.
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The inﬂammatory response attracts cytokines, prostaglandins, blood
cells, and growth and cytotoxic factors to the site of infection or injury
and also redirects blood ﬂow to these areas (Kawai and Akira, 2006);
this response induces local biochemical reactions, resulting in tissue re-
modeling (Kim et al., 2012). In myopia, similar structural modiﬁcations
occur, and it was therefore hypothesized that inﬂammation could play a
role in myopia progression.Fig. 2. Effect of atropine on the expression of genes and signaling pathways involved in tissue rem
the PI3K–AKT andMAPK pathways. ARPE-19 and primary retinal pigmented epithelial cells wer
harvested for western blot analysis to determine the phosphorylation status of ERK (Thr202/T
(Ser32). Fold changes of phosphorylated signaling molecules were normalized to levels of n
software. (b) Primary scleral ﬁbroblast cells were treated with or without 100 μM atropine f
ﬁbroblasts; nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). (c, d) Gelatin zym
ﬁbroblasts (d) treated with 1 μg/ml LPS with or without atropine. The MMP2 inhibitor diacereMyopia is more common among diabetic patients than in the
general population (38% vs. 27%) (Fledelius, 1983), and type I and
II diabetes mellitus are risk factors for myopia (Chen et al., 2008;
Cordain et al., 2002; Jacobsen et al., 2008; Tarczy-Hornoch et al.,
2006; Wu et al., 2005). Type 2 diabetes mellitus is an inﬂammatory
disease and is associated with elevated serum levels of IL-1β and -
6, TGF-β, and TNF-α (Donath and Shoelson, 2011). Similarly, visual
system dysfunction, such as myopia, has been reported in up to
30% of SLE patients. Moreover, the inﬂammatory condition dry eyeodeling. (a) Effect of atropine on LPS-induced activation ofNF-κB andAP1 via inhibition of
e treatedwith PBS (control), 100 ng/ml LPS, or LPS+ 100 μMatropine for 30min and then
yr204), AKT (Ser473), PI3K (p85(Tyr458)/p55(Tyr199)), NF-κB (p65, Ser536), and c-Fos
on-phosphorylated proteins. The intensities of each band were determined by ImageJ
or 24 h. Immunoﬂuorescence analysis of MMP2 and COL1 expression in primary scleral
ograph of pro- and active MMP2 in ARPE-19 retinal pigment epithelial cells (c) or scleral
in was used as the control.
Fig. 3. Levels of tissue remodeling proteins and inﬂammatorymolecules increase over time in occluded eyes.MFDwas induced in Syrian hamsters, and the occluded eyeswere collected at
days 0, 2, 7, 14 and 21. (a) Immunohistochemical analysis of TGF-β, MMP2, and collagen I expression in occluded eyes. (b) Immunohistochemical analysis of NF-κB, c-FOS, TNF-α, IL-6, and
IL-10 levels in occluded eyes.
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of SLE (Palejwala et al., 2012; Sivaraj et al., 2007). Uveitis can induce
acute or constitutive myopia and myopic shift, whereas acute myo-
pia is observed in patients with acute scleritis (Gross et al., 1993).
Among all uveitis cases, approximately 6% are found in individuals
under 18 years of age (Nguyen and Foster, 1998), and the most com-
mon cause of intraocular inﬂammation is JCA-associated uveitis
(Paivonsalo-Hietanen et al., 2000). Among all JCA patients, approxi-
mately 10–20% suffer from chronic uveitis (Boone et al., 1998; Kesen
et al., 2008; Kotaniemi et al., 1999; Malleson, 1998). Chronic uveitis
is generally asymptomatic in children with JCA, but the disease pro-
gresses gradually, possibly resulting in blindness. The high inci-
dence of uveitis among JCA patients may increase the progression
of myopia. Higher expression levels of the inﬂammatory cytokines
IL-6 and TNF-αwere found in the aqueous humor of uveitis patients
(Chen et al., 2015). These increased levels of IL-6 and TNF-α in the
eye support the progression of myopia. The systemic acute or chron-
ic inﬂammatory state associated with these diseases likely increases
the occurrence of myopia.
Myopia has been linked to urbanization; however, in this study,
no differences were noted between T1D, uveitis, and SLE patients
and control subjects in terms of urbanization (Tables 1 and 2).
The results indicate that the inﬂammatory reactions initiated by
T1D, uveitis, and SLE are major contributors to the incidence of my-
opia. Signiﬁcantly, in the T1D, uveitis and SLE groups, a higher inci-
dence of myopia was observed among younger patients (under
12 years of age) than in patients aged 13–18 years, which suggests
that the younger one affected by inﬂammation, the higher risk of
myopia.
In MFD hamsters, inﬂammatory genes were differentially expressed
in the sclera and retina. Furthermore, consistent with previous reports
(Guggenheim and McBrien, 1996; Honda et al., 1996; Lind et al., 1998;
Seko et al., 1995), TGF-β and MMP2 transcript levels were elevated in
myopic as compared to non-myopic eyes; in contrast, COL1 expres-
sion was downregulated. These changes were reversed by applica-
tion of atropine in cultured primary sclera ﬁbroblasts and retinal
pigment epithelial cells as well as in vivo. The increase in RE by
CSA treatment and decrease in RE by LPS or PGN demonstrate that
inﬂammation plays a key role in myopia progression. In addition to
hamsters, we also found a similar increase in the inﬂammatoryresponse in both albino guinea pigs and pigmented guinea pigs.
MFD was induced in guinea pigs by covering the right eye with a
cloth attached to the skin at a distance of at least 1 cm from the
eye (Supplementary Fig. 5). Atropine (1%) was applied to the eyes
of the guinea pigs, and the RE and axial lengths were measured on
day 21. The change in RE for the PBS-treated group was −9.22 ±
0.93 D for MFD eyes. Upon treatment with atropine, these values
changed to −6.79 ± 1.00. The change in axial length for the PBS-
treated group was 1.17 ± 0.01 mm for MFD eyes. Upon treatment
with atropine, these values changed to 1.14 ± 0.01 mm (Supple-
mentary Table 1). Both RE and axial length showed statistically sig-
niﬁcant differences between PBS- and atropine-treated MFD eyes
(all p b 0.005). The expression levels of MMP2, TGF-β, and c-Fos in-
creased in myopic eyes, whereas that of COLI decreased. Atropine
treatment decreased MMP2, TGF-β, and c-Fos expression and in-
creased COL1 expression in the sclera and retina of MFD eyes com-
pared to eyes treated with PBS (Supplementary Figs. 6, 7). IL-10
was downregulated by MFD, and this effect was suppressed by atro-
pine (Supplementary Fig. 7). These results reveal consistent out-
comes for a different MFD method as well as in a different species
of animal.
Studies in various cell lines have shown that activation of
mAChRs is associated with airway inﬂammation. Activation of
mAChR stimulates the release of the pro-inﬂammatory chemotactic
factor leukotriene B4 from macrophages, which can be inhibited by
the mAChR M3 inhibitor tiotropium (Buhling et al., 2007). In guinea
pigs, atropine inhibited the pro-inﬂammatory vagovagal reﬂex, eo-
sinophil inﬁltration into the lung, and lung neutrophilia induced by
diesel soot (McQueen et al., 2007). Application of an M3 mAChR in-
hibitor reduced airway inﬂammation and lowered IL-4, -5, and -13
and TGF-β1 expression in the bronchoalveolar lavage ﬂuid in
acute or chronic asthma (Ohta et al., 2010). LPS-induced acute
lung injury was inhibited by atropine and mAChR M3 antagonist
treatment, as indicated by a decrease in neutrophil inﬁltration and
downregulation of TNF-α and IL-6 expression (Xu et al., 2012).
Taken together, these results indicate that the inﬂammatory re-
sponse is increased by mAChR activation, and is suppressed by
mAChR antagonism.
TGF-β has been implicated in many human diseases and disorders,
including myopia, although it is not known whether TGF-β is produced
Fig. 4. Effect of atropine onmyopia progression. (a) The REwas determined as the difference in dioptermeasurements taken after and beforeMFD. The ANOVA testwas used to determine
signiﬁcant differences (pb 0.0001), andDunnett'smultiple comparisons testwas used for paired comparisons between PBS- and atropine-treated eyes. p b 0.05was considered statistically
signiﬁcant. (b) The axial lengthwas determined as the difference in dioptermeasurements taken after and beforeMFD. ANOVAwas used to determine signiﬁcant differences (p=0.0042)
and Dunnett's multiple comparisons test was used for paired comparisons between PBS- and atropine-treated eyes. p b 0.05 was considered statistically signiﬁcant. (c–g)
Immunohistochemical analysis of mAChR1 and 3 (c), MMP2 and COL1 (d), TGF-β (e), c-FOS and NF-κB (f), and IL-6, TNF-α, and IL-10 (g) in control eyes (control [L]), occluded eyes
(control [R]), 1% atropine-treated control eyes (atropine [L]), and 1% atropine-treated occluded eyes (atropine [R]).
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its expression in scleral tissue (Li et al., 1999). TGF-β, IL-6, and TNF-
α activate NF-κB, an important transcription factor in themodulation of the inﬂammatory response. One target of TGF-β sig-
naling via NF-κB is MMP2 (Wang et al., 2011b), which can cleave
collagens including COL1, thereby promoting myopia progression
Fig. 5.Effect of suppressing or increasing inﬂammation in the eye onmyopia progression. (a) TheREwas determined as thedifference indioptermeasurements taken after andbeforeMFD
in hamsters treated for 21 days with 3% CSA. (b) Immunohistochemical analysis of TGF-β and MMP2 expression in control eyes (control [L]), occluded eyes (control [R]), 3% CSA-treated
control eyes (CSA [L]), and 3% CSA-treated occluded eyes (CSA [R]). (c) The refractive error was determined as the difference in diopter measurements taken after and before MFD in
hamsters treated for 21 days with LPS or PGN. *Indicates statistically signiﬁcant compared with the untreated control. (d) Immunohistochemical analysis of TGF-β and MMP2
expression in control eyes ([L]) and form-deprived occluded eyes ([R]) with or without LPS or PGN. (e) The refractive error was determined as the difference in diopter measurements
in hamsters treated for 21 days with LPS or PGN. *Indicates statistically signiﬁcant compared with PBS-treated control. (f) Immunohistochemical analysis of TGF-β, MMP2, and
collagen I expression in eyes treated with or without LPS or PGN.
278 H.-J. Lin et al. / EBioMedicine 10 (2016) 269–281(Frost and Norton, 2007; Lin et al., 2008; Seko et al., 2008; Wang
et al., 2011a). Signals mediated by TGF-β, IL-6 and TNF-α predomi-
nantly culminate in the activation of NF-κB, a transcription factor
that is important for mediating inﬂammation. In this pathway, thesignal from pro-inﬂammatory mediators leads to the activation of
IκB kinase α/β, which then phosphorylates IκB; its subsequent deg-
radation activates NF-κB, which drives the production of numerous
pro-inﬂammatory cytokines, including TNF-α and IL-6. Another
Fig. 6. Expression levels of inﬂammation-related transcription factors and cytokines in cyclosporine A-treated myopic eyes. (a) Immunohistochemical analysis of c-Fos and NF-κB
expression in control eyes (control [L]), occluded eyes (control [R]), 3% CSA-treated control eyes (CSA [L]), and 1% atropine-treated occluded eyes (CSA [R]). (b) Immunohistochemical
analysis of IL-6, TNF-α, and IL-10 expression in control eyes (control [L]), occluded eyes (control [R]), 3% CSA-treated control eyes (CSA [L]), and 3% CSA-treated occluded eyes (CSA [R]).
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kine expression is activator protein 1 (AP1), the activation of
which is mediated by the phosphorylation and activation of mito-
gen-associated protein kinases (MAPKs) such as Janus kinase
(JNK), p38, or extracellular signal-regulated kinase (ERK), which
then activate c-Jun. and/or c-Fos to promote inﬂammatory cytokine
expression. NF-κB and AP1 also stimulate the production of pro-in-
ﬂammatory cytokines, and there is considerable overlap in the tar-
get genes activated by these two factors (Huang et al., 2009;
Nguyen et al., 2007; Ogawa et al., 2004). TNF-α may act in a para-
crine feedback loop in the retina or sclera to activate NF-κB during
myopia progression. It was shown that their activation by LPS was
suppressed by atropine in retinal cells (Fig. 7).
In this study, we found a link between inﬂammatory reactions
and the progression of myopia. Atropine has side effects such as
photophobia and cycloplegia, which is why it is rarely used as a
treatment for myopia in Western countries. This discovery is impor-
tant for ophthalmologists because it provides them with a potential
treatment alternative to atropine that they can offer to their pa-
tients. In conclusion, these ﬁndings provide evidence for theinvolvement of inﬂammatory responses in myopia and suggest
that treatment with atropine or anti-inﬂammatory agents can effec-
tively inhibit myopia progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.021.
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